medigraphic.com

2013, Number 3

<< Back Next >>

Rev Hosp Jua Mex 2013; 80 (3)

Síndrome de Steele Richardson y Olzewski (parálisis supranuclear progresiva). Reporte de un caso clínico y revisión bibliográfica

Gómez-Valdés OA, Chávez-Ocaña S, González-Muñoz A

Language: Spanish
References: 24
Page: 196-201
PDF size: 304.76 Kb.


ABSTRACT

Progressive supranuclear palsy (PSP) is a neurodegenerative disease of the dorsal midbrain, superior colliculus and red nuclei that may have or not a genetic cause, since there have been cases of family inheritance by an autosomal dominant disorder given by 31-32 aminoacids encoded by exons 9-12 in the Tau gene located on chromosome 17q21.31, which favors the accumulation of tau protein in the cerebral cortex. The prevalence of this disease is 1.39 cases per 100,000 population in the United States , which 4-6% affects patients with parkinsonism, considered a very rare disease. Currently there is no accurate information on the number of cases reported in our country, so thats why a case in a Mexican patient calls attention and it should be reported. This disease usually occurs between 45 and 75 years old with a different combination of symptoms ranging from difficulty with balance, sudden drops, visual disorders and eye, slurred speech and dysphagia. We describe the case of a man of 79 years old, came to the emergency room for hypoglycemia and progressive neurological deterioration with clinical data of PSP.


REFERENCES

  1. Ropper H. Allan, Samuels A. Martin. Adams y Victor Principios de Neurología. 9a Ed. Mc Graw Hill; 2011, p. 1046-8.

  2. Samandouras G. The Neurosurgeon’s Handbook. 1st Ed. Oxford; 2010, p. 9-10.

  3. Maurice Victor, Ropper Allan H, Adams y Victor. Manual de neurología. 7a Ed. Mc Graw Hill; 2003, p. 540-1.

  4. Andrea Righini MR. Imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and parkinson disease. AJNR Am J Neuroradiol 2004; 25: 927-32.

  5. Erbetta A, Mandelli ML. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Neuroradiol 2009; 1482-7.

  6. Ito S, Shiari W. Putaminal hyperintensity on T1 weighted MR imaging in patients with the Parkinson variant of multiple system atrophy. AJNR Neuroradiol 2009; 689-92.

  7. Rademakers R. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Human Molecular Genetics 2005; 14(21): 3281-92.

  8. Rohrer JD. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Department of Neurodegenerative Disease 2010; 149-52.

  9. Chen AL. The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis, Veterans Affairs Medical Center, University Hospitals Case Medical Center, Cleveland, OH, USA, December, 2010; 4-12.

  10. Dugger NB. Disease specificity and pathologic progression of Tau pathology in brainstem nuclei of Alzheimer’s disease and progressive supranuclear palsy. Neurosci Lett 2011; 491(2): 122-6.

  11. Rollan Y, Verín M. A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability. J Neurol Neurosurg Psychiatry 2011; 82: 1025-32.

  12. Reta L. Weston Institute, UCL Institute of Neurology, University College London, London , UK; c Prince of Wales Medical Research Institute, Randwick, NSW, Australia. Neurodegenerative Disease 2011; 8: 149-52.

  13. Evidente H. Gerald Virgilio. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord 2011; 17(5): 365-71.

  14. Günter U. Höglinger. Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy. Nat Genet 2012; 43(7): 699-705.

  15. Botrán-Fernández R. Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord 2011; 17(9): 683-8.

  16. Reyes FJ. Selective tau tyrosine nitration in non-AD tauopathies. Acta Neuropathol 2012; 123(1): 119-32.

  17. Payan MA. Christine. Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS-PARKINSON PLUS SCALE. PLoS ONE 2011; 1-9.

  18. Kouri N. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain a J Neurol 2011; 134: 3264-75.

  19. Schneider R. Influence of orbital eye position on vertical saccades in progressive supranuclear palsy. Ann N Y Acad Sci 2011; 1233(1): 64-70.

  20. Whitwell LJ. Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. NIH. Parkinsonism Relat Disord 2012; 18(3): 252-6.

  21. Potts FL. Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. Medical Genetics 2012; 1-8.

  22. Champoux F, Paiement P, Lassonde M, Gagne JP. Auditory processing in a patient with a unilateral lesion of the inferior colliculus. Eur J Neurosci 2007; 25: 291-7.

  23. Ghosh PCB. Social cognitive deficits and their neural correlates in progressive supranuclear palsy. Brain, J Neurol 2012; 135: 2089-102.

  24. Oliveira, Scott, WK, Zhang. Linkage disequilibrium and haplotype tagging polymorphisms in the Tau H1 haplotype. Neurogenetics 2004; 147-55.




2020     |     www.medigraphic.com